NASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $10.71 +0.62 (+6.14%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$10.99 +0.28 (+2.61%) As of 05/2/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Oruka Therapeutics Stock (NASDAQ:ORKA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$10.07▼$10.9550-Day Range$6.78▼$12.5052-Week Range$5.49▼$31.13Volume122,445 shsAverage Volume234,421 shsMarket Capitalization$400.99 millionP/E RatioN/ADividend YieldN/APrice Target$39.86Consensus RatingBuy Company OverviewOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Read More… Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 369th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOruka Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oruka Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ORKA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ORKA. News and Social Media2.1 / 5News Sentiment0.70 News SentimentOruka Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,128,456.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.67% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Stock News HeadlinesQ1 EPS Estimates for Oruka Therapeutics Cut by HC WainwrightMay 3 at 1:12 AM | americanbankingnews.comQ1 Earnings Estimate for ORKA Issued By HC WainwrightMay 2 at 3:27 AM | americanbankingnews.comElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech shift. Here’s how to position early.May 4, 2025 | InvestorPlace (Ad)Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Buy" from BrokeragesMay 1 at 1:13 AM | americanbankingnews.comOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comOruka Therapeutics announces preclinical data for ORKA-002March 7, 2025 | markets.businessinsider.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $19.39 on January 1st, 2025. Since then, ORKA stock has decreased by 44.8% and is now trading at $10.71. View the best growth stocks for 2025 here. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Thursday, March, 6th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.19. Who are Oruka Therapeutics' major shareholders? Oruka Therapeutics' top institutional shareholders include Cannon Global Investment Management LLC (0.05%). View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and Skye Bioscience (SKYE). Company Calendar Last Earnings3/06/2025Today5/04/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$39.86 High Stock Price Target$49.00 Low Stock Price Target$20.00 Potential Upside/Downside+272.1%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($5.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.96% Return on Assets-21.22% Debt Debt-to-Equity RatioN/A Current Ratio22.89 Quick Ratio22.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares37,441,000Free Float27,065,000Market Cap$400.99 million OptionableN/A Beta0.25 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ORKA) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.